drugset

drugset / Trial / NCT00249041

Enbrel Liquid Immunogenicity Protocol

NCT00249041 ↗

Phase 3 Completed 447 enrolled Amgen Immunex Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis

Timeline

Start: 2005-10
Primary completion: 2006-12
Completion: 2007-03

Publications

Results Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. J Rheumatol. 2010 May;37(5):1035-41. doi: 10.3899/jrheum.090704. Epub 2010 Feb 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous

Indications